Provectus Biopharmaceuticals (PVCT) Short Interest Ratio & Short Volume $0.10 0.00 (-0.20%) As of 03:57 PM Eastern Add Compare Share Share Short Interest Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestBuy This Stock Provectus Biopharmaceuticals Short Interest DataProvectus Biopharmaceuticals (PVCT) has a short interest of 500 shares, representing 0.00% of the float (the number of shares available for trading by the public). This marks a -97.14% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 235,500 shares to cover all short positions.Current Short Interest500 sharesPrevious Short Interest17,500 sharesChange Vs. Previous Month-97.14%Dollar Volume Sold Short$50.65Short Interest Ratio0.0 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares420,280,000 sharesShort Percent of Float0.00%Today's Trading Volume91,283 sharesAverage Trading Volume235,500 sharesToday's Volume Vs. Average39% Short Selling Provectus Biopharmaceuticals? Sign up to receive the latest short interest report for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPVCT Short Interest Over TimePVCT Days to Cover Over TimePVCT Percentage of Float Shorted Over Time Remove Ads Provectus Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/2025500 shares $50.65 -97.1%0.0%0 $0.10 2/28/202517,500 shares $1,862.00 +3,400.0%0.0%0.1 $0.11 2/15/2025500 shares $52.20 No Change0.0%0 $0.10 1/31/2025500 shares $52.80 -97.2%N/A0 $0.11 1/15/202518,000 shares $2,086.20 +520.7%N/A0 $0.12 12/31/20242,900 shares $348.29 -65.9%N/A0 $0.12 12/15/20248,500 shares $1,088.00 +214.8%N/A0 $0.13 11/30/20242,700 shares $318.60 +440.0%N/A0 $0.12 11/15/2024500 shares $55.05 -99.2%N/A0 $0.11 10/31/202465,600 shares $7,052.00 +1,626.3%N/A0.2 $0.11 Get the Latest News and Ratings for PVCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 10/15/20243,800 shares $410.02 -93.5%N/A0 $0.11 9/30/202458,700 shares $5,746.73 +3,568.8%N/A0.1 $0.10 9/15/20241,600 shares $159.76 -48.4%N/A0 $0.10 8/31/20243,100 shares $279.00 -91.8%N/A0 $0.09 8/15/202437,800 shares $3,277.26 +404.0%N/A0.1 $0.09 7/31/20247,500 shares $768.75 +87.5%N/A0 $0.10 7/15/20244,000 shares $458.80 +700.0%N/A0 $0.11 6/30/2024500 shares $63.05 No ChangeN/A0 $0.13 6/15/2024500 shares $79.50 -87.8%N/A0 $0.16 5/31/20244,100 shares $690.03 +720.0%N/A0 $0.17 5/15/2024500 shares $97.15 -99.7%N/A0 $0.19 4/30/2024142,600 shares $28,377.40 +127.8%N/A0.4 $0.20 4/15/202462,600 shares $10,485.50 -67.2%N/A0.1 $0.17 3/31/2024190,800 shares $34,887.78 +1,700.0%N/A0.3 $0.18 3/15/202410,600 shares $2,299.14 -85.7%N/A0 $0.22 2/29/202474,000 shares $11,003.80 -4.0%N/A0.2 $0.15 2/15/202477,100 shares $10,470.18 +1,780.5%N/A0.2 $0.14 1/15/202416,300 shares $1,677.27 -50.6%N/A0.1 $0.10 12/31/202333,000 shares $3,168.00 +89.7%N/A0.1 $0.10 12/15/202317,400 shares $1,896.60 +3.0%N/A0 $0.11 11/30/202316,900 shares $2,535.00 -46.5%N/A0 $0.15 11/15/202331,600 shares $4,740.00 +179.7%N/A0 $0.15 10/31/202311,300 shares $904.00 +2,160.0%N/A0 $0.08 10/15/2023500 shares $35.00 No ChangeN/A0 $0.07 9/30/2023500 shares $42.25 -94.8%N/A0 $0.08 9/15/20239,600 shares $943.68 +100.0%N/A0.1 $0.10 8/31/20234,800 shares $489.60 -46.1%N/A0 $0.10 8/15/20238,900 shares $845.50 +1,680.0%N/A0 $0.10 7/31/2023500 shares $54.45 -97.8%N/A0 $0.11 7/15/202322,300 shares $2,796.42 -64.6%N/A0.1 $0.13Trump’s Final Plan (Ad)Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.Click here for the full story. 6/30/202363,000 shares $7,125.30 +63.6%N/A0.1 $0.11 6/15/202338,500 shares $4,581.50 +7,600.0%N/A0.1 $0.12 5/31/2023500 shares $67.95 -99.4%N/A0 $0.14 5/15/202381,400 shares $11,387.86 +13,466.7%N/A0.4 $0.14 4/30/2023600 shares $80.22 -81.3%N/A0 $0.13 4/15/20233,200 shares $489.60 -96.4%N/A0 $0.15 3/31/202389,000 shares $14,685.00 +88,900.0%N/A0.3 $0.17 3/15/2023100 shares $15.40 -99.9%N/A0 $0.15 2/28/2023116,600 shares $18,772.60 +3,051.4%N/A0.3 $0.16 2/15/20233,700 shares $395.53 -89.5%N/A0 $0.11 1/31/202335,200 shares $4,509.12 +262.9%N/A0.1 $0.13 1/15/20239,700 shares $1,286.71 +9,600.0%N/A0 $0.13 12/30/2022100 shares $10.83 -99.0%N/A0 $0.11 12/15/202210,000 shares $1,099.00 -66.6%N/A0 $0.11 11/30/202229,900 shares $2,780.70 -45.5%N/A0 $0.09 11/15/202254,900 shares $2,843.82 +54,800.0%N/A0.1 $0.05 10/31/2022100 shares $5.00 No ChangeN/A0 $0.05 10/15/2022100 shares $4.85 No ChangeN/A0 $0.05 9/30/2022100 shares $4.90 -99.6%N/A0 $0.05 9/15/202225,500 shares $1,351.50 +8.5%N/A0.1 $0.05 8/31/202223,500 shares $1,280.75 +2,511.1%N/A0.1 $0.05 8/15/2022900 shares $49.50 +80.0%N/A0 $0.06 7/31/2022500 shares $29.00 +400.0%N/A0 $0.06 7/15/2022100 shares $5.99 -99.6%N/A0 $0.06 6/30/202226,200 shares $1,419.28 +26,100.0%N/A0.1 $0.05 6/15/2022100 shares $5.30 -96.8%N/A0 $0.05 5/31/20223,100 shares $186.00 -54.4%N/A0 $0.06 5/15/20226,800 shares $357.68 +3,300.0%N/A0 $0.05 4/30/2022200 shares $12.28 +100.0%N/A0 $0.06 4/15/2022100 shares $5.86 No ChangeN/A0 $0.06 3/31/2022100 shares $6.74 No ChangeN/A0 $0.07 3/15/2022100 shares $6.92 -96.7%N/A0 $0.07 2/28/20223,000 shares $206.70 +2,900.0%N/A0 $0.07 2/15/2022100 shares $7.00 -98.7%N/A0 $0.07 1/31/20227,700 shares $500.50 -85.4%N/A0 $0.07 1/15/202252,600 shares $3,682.00 +39.2%N/A0.1 $0.07 12/31/202137,800 shares $2,079.00 +37,700.0%N/A0 $0.06 12/15/2021100 shares $5.03 -93.8%N/A0 $0.05 11/30/20211,600 shares $85.76 -61.0%N/A0 $0.05 11/15/20214,100 shares $213.61 +4,000.0%N/A0 $0.05 10/29/2021100 shares $5.62 -99.9%N/A0 $0.06 10/15/202190,700 shares $5,587.12 -24.6%N/A0.4 $0.06 9/30/2021120,300 shares $7,819.50 +55.8%N/A0.3 $0.07 9/15/202177,200 shares $4,863.60 -45.4%N/A0.2 $0.06 8/31/2021141,300 shares $8,619.30 -29.4%N/A0.1 $0.06 8/13/2021200,200 shares $13,913.90 -22.3%N/A0.5 $0.07 7/30/2021257,500 shares $17,896.25 +29.7%N/A1 $0.07 7/15/2021198,600 shares $13,902.00 +13.6%N/A0.4 $0.07 6/30/2021174,900 shares $11,980.65 -3.6%N/A0.7 $0.07 6/15/2021181,500 shares $12,668.70 -10.4%N/A0.3 $0.07Trump’s Final Plan (Ad)Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.Click here for the full story. 5/28/2021202,600 shares $14,911.36 +9.0%N/A0.5 $0.07 5/14/2021185,800 shares $12,430.02 +16.1%N/A0.6 $0.07 4/30/2021160,000 shares $10,400.00 No ChangeN/A0.3 $0.07 4/15/2021160,000 shares $10,752.00 -14.5%N/A0.5 $0.07 3/31/2021187,200 shares $13,122.72 +10.1%N/A0.3 $0.07 3/15/2021170,000 shares $11,645.00 +6.3%N/A0.5 $0.07 2/26/2021160,000 shares $11,680.00 -34.0%N/A0.3 $0.07 2/12/2021242,400 shares $17,695.20 +25.9%N/A0.3 $0.07 1/29/2021192,600 shares $14,445.00 -54.3%N/A0.1 $0.08 1/15/2021299,400 shares $20,898.12 +76.1%N/A0.4 $0.07 12/31/2020160,500 shares $9,292.95 -46.4%N/A0.3 $0.06 12/15/2020299,400 shares $17,514.90 +76.1%N/A0.4 $0.06 11/30/2020170,000 shares $10,880.00 -1.4%N/A0.3 $0.06 11/15/2020172,400 shares $11,585.28 -46.8%N/A0.6 $0.07 10/30/2020324,100 shares $22,038.80 +23.8%N/A0.9 $0.07 10/15/2020261,700 shares $19,889.20 -44.8%N/A0.5 $0.08 9/30/2020473,700 shares $41,022.42 +194.6%N/A0.7 $0.09 9/15/2020160,800 shares $11,674.08 +0.2%N/A0.4 $0.07 8/31/2020160,500 shares $12,968.40 -42.0%N/A0.3 $0.08 8/14/2020276,700 shares $26,148.15 +3,493.5%N/A0.2 $0.09 7/31/20207,700 shares $553.63 -67.4%N/A0 $0.07 7/15/202023,600 shares $1,413.64 +81.5%N/A0.1 $0.06 6/30/202013,000 shares $585.00 +20.4%N/A0 $0.05 6/15/202010,800 shares $509.76 +2,060.0%N/A0 $0.05 5/29/2020500 shares $22.30 -80.0%N/A0 $0.04 5/15/20202,500 shares $105.25 +400.0%N/A0 $0.04 4/30/2020500 shares $21.00 No ChangeN/A0 $0.04 4/15/2020500 shares $24.15 -99.2%N/A0 $0.05 3/31/202061,000 shares $2,440.00 +634.9%N/A0.1 $0.04 PVCT Short Interest - Frequently Asked Questions What is Provectus Biopharmaceuticals' current short interest? Short interest is the volume of Provectus Biopharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of March 15th, investors have sold 500 shares of PVCT short. 0.00% of Provectus Biopharmaceuticals' shares are currently sold short. Learn More on Provectus Biopharmaceuticals' current short interest. What is a good short interest percentage for Provectus Biopharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.00% of Provectus Biopharmaceuticals' floating shares are currently sold short. Is Provectus Biopharmaceuticals' short interest increasing or decreasing? Provectus Biopharmaceuticals saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 500 shares, a drop of 97.1% from the previous total of 17,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Provectus Biopharmaceuticals' short interest compare to its competitors? 0.00% of Provectus Biopharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Provectus Biopharmaceuticals: Innate Pharma S.A. (0.73%), Puma Biotechnology, Inc. (7.18%), ADC Therapeutics SA (6.01%), Molecular Partners AG (0.11%), C4 Therapeutics, Inc. (12.66%), Lyell Immunopharma, Inc. (4.78%), scPharmaceuticals Inc. (11.99%), Lexeo Therapeutics, Inc. (8.90%), Larimar Therapeutics, Inc. (8.25%), Inventiva S.A. (0.97%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short Provectus Biopharmaceuticals stock? Short selling PVCT is an investing strategy that aims to generate trading profit from Provectus Biopharmaceuticals as its price is falling. PVCT shares are trading down $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Provectus Biopharmaceuticals? A short squeeze for Provectus Biopharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PVCT, which in turn drives the price of the stock up even further. How often is Provectus Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PVCT, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies IPHA Short Interest Data PBYI Short Interest Data ADCT Short Interest Data MOLN Short Interest Data CCCC Short Interest Data LYEL Short Interest Data SCPH Short Interest Data LXEO Short Interest Data LRMR Short Interest Data IVA Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:PVCT) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provectus Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
